Profit before tax (PBT) dropped 51.9% YoY to Rs 83.77 crore in Q2 FY26

Adjusted EBITDA for the quarter was Rs 128.9 crore, with Adjusted EBITDA margins of 23.2%, reflecting the lower volumes, upfront investments in employee costs and certain transition and remediation costs.

On half-yearly basis, the company’s consolidated net profit tumbled 42.5% to Rs 122.96 crore despite of 1.2% increase in revenue from operations to Rs 1,104.88 crore in H1 FY26 over H1 FY25.

On the outlook front, the company stated that it remains on track to achieve its $ 1 billion (Rs 8,500 crore) revenue target by 2030, with mid-30s EBITDA margins. Investments in the team, business development and broadening of customer base over the last 12 months will help to achieve the targets.

Vivek Sharma, executive chairman, said: “As we move from integration to capability amplification, Cohance is now firmly focused on building the science platforms, operational backbone, and governance needed to power our next phase of growth.

The revised organization structure strengthened leadership team, position us strongly on the path toward our US$1 billion vision. We’ve unveiled our new brand identity at CPHI Frankfurt, deepened our customer engagements across the U.S., Europe, and Japan, and continue to attract exceptional talent across our businesses.

While near-term challenges such as pharma destocking, biotech funding delays, and the temporary Nacharam plant shutdown have impacted reported growth, our fundamentals remain strong. We achieved a key regulatory milestone with a late-phase molecule approval in the U.S., added new biotech partnerships, and successfully completed multiple customer audits. Demand from large innovators remains healthy, and we see clear tailwinds as global customers increasingly seek to diversify supply chains and partner with technology-led CDMOs like Cohance.”

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.